SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Nebius Group NV is a technology company that provides infrastructure and services to AI builders worldwide. It offers Nebius AI, an AI-centric cloud platform provides full-stack infrastructure, including large-scale GPU clusters, cloud services, and developer tools. The company also operates through specialized brands: Toloka AI, which partners in data for generative AI development; TripleTen, an edtech platform focused on re-skilling individuals for tech careers; and Avride, which develops autonomous driving technology. Nebius Group was founded by Elena Kolmanovskaya, Ilya Segalovich, Mikhail Fadeev, and Arkady Volozh in 1989 and is headquartered in Amsterdam, the Netherlands.

Nebius Group N.V. - Ordinary Shares - Class A

Nebius Group N.V. 

Nebius Group is trending as investors react to a significant price target hike from Bank of America and anticipation ahead of the upcoming earnings release. The community remains deeply divided, with bulls pointing to the firm's rapid revenue growth and infrastructure expansion, while bears continue to raise concerns regarding high valuations, aggressive capital expenditures, and potential dilution risks.

WORK Medical Technology Group Ltd. engages in the development of health instruments. It manufactures and sells medical devices, including endotracheal tubes, laryngeal mask airways, heat and moisture exchanging filters, disposable breathing circuits, nebulizer kits, and yankauer suction sets. The company was founded on March 1, 2022 and is headquartered in Hangzhou, China.

Work Medical Technology Group Ltd - Ordinary Shares - Class A

Work Medical Technology Group Ltd

Work Medical Technology Group Ltd (WOK) is experiencing extreme volatility and intense community speculation following a rapid, massive decline from its overnight highs. Investors are actively debating whether the stock represents a typical Chinese pump-and-dump scheme or a high-risk opportunity for a technical rebound.

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

SELLAS Life Sciences is trending as the community reacts to the REGAL trial reaching 78 of the 80 required patient events, signaling that final data and trial unblinding are imminent. Investors are actively discussing the potential for a massive short squeeze due to high short interest, while long-term shareholders remain focused on the potential of the GPS treatment to transform AML care and attract significant buyout interest.

Eos Energy Enterprises, Inc. designs, manufactures, and deploys battery storage solutions for the electricity industry. It offers the Eos Znyth DC battery system product which designs to meet the requirements of the grid-scale energy storage market. The company was founded in 2008 and is headquartered in Edison, NJ.

Eos Energy Enterprises Inc - Ordinary Shares - Class A

Eos Energy Enterprises is trending as investors react to a significant partnership with Turbine-X to deploy American-made long-duration energy storage for AI-driven data centers. The community is actively debating the company's ability to scale manufacturing and execute on its growing commercial pipeline, with many traders closely monitoring high short interest and potential for a squeeze.

Red Cat Holdings, Inc. provides products, services and solutions to the drone industry. It also engages in the provision of distributed data storage, analytics and services for the drone industry.The firm product include Dronebox, which is a blockchain technology that records, stores and analyzes flight data and information from a drone. It operates through the Enterprise Segment. The Enterprise Segment will focus on developing a hardware enabled software platform of services and solutions to government and commercial enterprises and the military. The company was founded by Jeffrey M. Thompson in February 1984 and is headquartered in San Juan, Puerto Rico.

Red Cat Holdings Inc

Red Cat Holdings is facing intense volatility as shareholders react to a significant public offering priced at a discount to market levels. While some investors express frustration over the timing and dilutive nature of the raise, others are debating whether the capital influx positions the company to aggressively scale production and pursue strategic M&A within the high-demand defense drone sector.

SPDR S&P 500 ETF TRUST - SPDR S&P 500 ETF Trust

The SPY is trending as investors weigh hot inflation data against an aggressive corporate delegation to China, with market participants debating whether the resilience of tech-heavy sectors signals an unstoppable rally or a bubble fueled by complacency. The community is sharply divided, with bulls pointing to the strength of AI-driven capital expenditure and momentum, while bears remain focused on rising yields, elevated oil prices, and the potential for a liquidity-driven correction.

Invesco QQQ Trust Series 1 - Invesco QQQ Trust Series 1

The market is showing extreme resilience and aggressive dip-buying behavior despite lingering concerns over hot producer inflation data, geopolitical tensions, and persistent oil price pressures. Investors are heavily focused on the implications of AI-driven capital expenditure and high-level corporate trade delegations to China, fueling a 'buy the dip' sentiment that continuously defies negative macro catalysts.

Alibaba Group Holding Ltd. engages in providing technology infrastructure and marketing reach. It operates through the following business segments: China Commerce, International Commerce, Local Consumer Services, Cainiao, Cloud, Digital Media and Entertainment, and Innovation Initiatives and Others segments. The Core Commerce segment consists of platforms operating in retail and wholesale. The China Commerce segment includes China commerce retail and wholesale businesses. The International Commerce segment focuses on international commerce retail and wholesale businesses. The Local Consumer Services segment is involved in To-Home businesses, which include Ele.me, local services and delivery platform, and Taoxianda, and To-Destination segment businesses which include Amap, the provider of mobile digital map, navigation and real-time traffic information, and restaurant and local services guide platform. The Cainiao segment has Cainiao Network and offers domestic and international one-stop-shop logistics services and supply chain management solution. The Cloud segment includes Alibaba Cloud and DingTalk. The company was founded by Chung Tsai and Yun Ma on June 28, 1999 and is headquartered in Hangzhou, China.

Alibaba Group Holding Ltd - ADR

Alibaba Group Holding Ltd

Alibaba is trending as investors react to a mixed earnings report that highlighted strong AI and cloud growth offset by concerns over heavy investment spending and compressed margins. While some in the community see the current price as a buying opportunity for a long-term AI play, others remain skeptical, dismissing the stock as a value trap prone to volatility.

NVIDIA Corp. engages in the design and manufacture of computer graphics processors, chipsets, and related multimedia software. It operates through the following segments: Graphics Processing Unit (GPU) and Compute & Networking. The Graphics segment includes GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, Quadro and NVIDIA RTX GPUs for enterprise workstation graphics, virtual GPU, or vGPU, software for cloud-based visual and virtual computing, automotive platforms for infotainment systems, and Omniverse Enterprise software for building and operating metaverse and 3D internet applications. The Compute & Networking segment consists of Data Center accelerated computing platforms and end-to-end networking platforms including Quantum for InfiniBand and Spectrum for Ethernet, NVIDIA DRIVE automated-driving platform and automotive development agreements, Jetson robotics and other embedded platforms, NVIDIA AI Enterprise and other software, and DGX Cloud software and services. The company was founded by Jen Hsun Huang, Chris A. Malachowsky, and Curtis R. Priem in April 1993 and is headquartered in Santa Clara, CA.

NVIDIA Corp

NVIDIA is trending as investors react to the surprise news that CEO Jensen Huang has joined President Trumps high-stakes delegation to Beijing, sparking optimism that export restrictions on advanced AI chips could be eased. The community is sharply divided between bulls anticipating a massive breakout toward 250+ heading into earnings and bears who remain cautious due to recent hot wholesale inflation data and broader macroeconomic uncertainty.

Intuitive Machines, Inc. is a space exploration, infrastructure, and services company, which engages in contributing to the establishment of cislunar infrastructure and helping to develop cislunar and deep space commerce. It offers space products and services. The company was founded by Stephen J. Altemus, Kam Ghaffarian, and Timothy P. Crain in 2013 and is headquartered in Houston, TX.

Intuitive Machines Inc - Ordinary Shares - Class A

Intuitive Machines Inc

Intuitive Machines is experiencing intense volatility as investors speculate on upcoming earnings and high-stakes contract awards. The community is sharply divided between bullish long-term supporters pointing to government contracts and space-sector growth, and bearish critics highlighting historical mission risks and speculative price swings.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>The warrants are priced at a 14% discount to Thursday’s closing price.</li><li>On Thursday, the biotech firm announced positive results from a Phase 2 trial of Ampligen to treat recurrent ovarian cancer patients.</li><li>Additional data on progression-free survival and overall survival are expected in January 2027.</li></ul>Shares of AIM ImmunoTech (AIM) plunged more than 35% on Friday after the biotech firm’s latest financing move, which allows certain accredited investors to exercise existing warrants for up to 8.7 million common shares at a reduced price.<a href="https://stocktwits.com/symbol/AIM">AIM shares</a> plunged to their lowest levels since June 2025, when it had executed a 1-for-100 reverse stock split.<h2 class="st-heading-2">AIM’s Discounted Pricing</h2>AIM ImmunoTech announced an agreement with certain accredited investors to exercise outstanding Class A, Class B, Class C, Class D, Class E, and Class F Warrants for $0.48 per share to raise $4.2 million in gross proceeds. This represents a 14% discount to Thursday’s closing price.The late-stage biotechnology company said the funds will mainly be used for working capital and other general corporate purposes.As part of the deal, investors who immediately exercise their existing warrants for cash will receive new unregistered warrants in a private placement, the company said. The new warrants will allow investors to buy up to 17.4 million common shares at $0.60 per share over the next five years.<h2 class="st-heading-2">AIM’s Positive Data From Ovarian Cancer Study</h2>This comes a day after AIM ImmunoTech announced positive final primary endpoint results from a Phase 2 clinical trial evaluating its experimental drug, Ampligen, in patients with recurrent ovarian cancer. The study tested Ampligen in combination with Merck’s immunotherapy Pembrolizumab and chemotherapy drug Cisplatin.Results showed a 50% objective response rate (ORR), with 21% of patients achieving complete responses. ORR measures the percentage of patients whose tumors either shrink or completely disappear after treatment.The trial also reported a 79% clinical benefit rate and a median overall survival of 32.5 months. Some patients experienced durable responses lasting more than 70 months. Importantly, no Grade 4 or Grade 5 toxicities were observed during the study. Additional data on progression-free survival and overall survival are expected in January 2027.<h2 class="st-heading-2">Retail Bets On AIM’s Cancer Therapy</h2>Retail sentiment on Stocktwits turned ‘extremely bullish’ from ‘bullish’ a day earlier, while message volumes on the platform rose by 200%.One user expects a potential for rerating.<stembedurl>https://stocktwits.com/GordoHLYK13/message/652758944</stembedurl>The stock has declined more than 70% so far this year.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/this-sub-1-stock-ripped-today-whats-driving-the-super-rally/cZX2AvTRegK">This Sub $1 Stock Ripped 150% Today – What’s Driving The Super Rally?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

S&P 500 Index trades listlessly ahead of Nvidia earnings. 

Why Did AIM Stock Plummet 35% Today?

AIM ImmunoTech announced an agreement with certain accredited investors to exercise outstanding warrants for $0.48 per share to raise $4.2 million in gross proceeds.

Equity

Biotech Breakthroughs and Strategic Pivots Fuel Market Momentum

Today’s action highlights biotech and healthcare innovators advancing novel therapies and strategic platforms amid rising demand for targeted treatments and efficient global access. With the biologics market surging toward $650 billion+ by 2030 and medical tourism accelerating, today's developments showcase capital-efficient clinical progress, high-growth partnerships, and operational scaling, creating compelling narratives in precision medicine, oncology adjuvants, and AI-enabled workforce solutions. $ARTL, $TGNT, $AIM, $YYGH

<ul class="summary-bullets"><li>While the patent was granted in September 2025, it had to pass a 6-month opposition period.</li><li>The patent, which expires in 2039, spans multiple cancer types, including pancreatic cancer.</li><li>AIM is seeking an orphan drug designation in Japan for its treatment.</li></ul>Shares of AIM ImmunoTech Inc (AIM) gave up some of its pre-market gains and was up more than 60% on Wednesday, after the company said that a Japanese patent using its proprietary Ampligen in combination with checkpoint inhibitors to treat cancer was fully approved in the country.While the patent was granted in September 2025, it had to pass a 6-month opposition period, AIM said. The patent, which expires in 2039, spans multiple cancer types, including pancreatic cancer. The company holds similar patents in the U.S. and the Netherlands.AIM, which already holds orphan drug designations for pancreatic cancer in the U.S. and Europe, also plans to seek a similar designation in Japan.<h2 class="st-heading-2">DURIPANC Study Update</h2>Earlier this month, AIM ImmunoTech partnered with Thermo Fisher Scientific’s PPD clinical research unit to design a planned Phase 3 trial of Ampligen for late-stage pancreatic cancer.&nbsp;The company also highlighted encouraging results from its ongoing DURIPANC study, including improvements in progression-free and overall survival. The trial is being conducted in collaboration with AstraZeneca and Erasmus Medical Center."Based on the success so far, as well as anticipated final patient enrollment later this year, we believe it is now time to start mapping out the next steps for AIM’s development of Ampligen as a therapy for pancreatic cancer," said CEO Thomas K. Equels."AIM’s scientific team will work closely with Thermo Fisher’s experts in the design of a Phase 3 study and we look forward to their expertise and guidance in this critical endeavor."<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Retail sentiment flipped to 'extremely bullish' from 'bearish' a day earlier, amid 'extremely high' message volumes.<img src="https://news.stocktwits-cdn.com/AIMS_jpg_04ac5ff737.webp" alt="AIMS.jpg">One user said the RSI has cooled and its time for the next leg of the rally.<stembedurl>https://stocktwits.com/Chessdoc/message/647888049</stembedurl>Year-to-date, the stock has climbed 1%.For updates and corrections, email newsroom[at]stocktwits[dot]com.&nbsp;

Why Did AIM Stock Jump 60% Today?

The company said that a patent using its proprietary cancer treatment method was fully approved in Japan.

Are Medical Stocks Lagging  AIM ImmunoTech (AIM) This Year?

Here is how AIM ImmunoTech Inc. (AIM) and Cullinan Therapeutics (CGEM) have performed compared to their sector so far this year.

Is AIM ImmunoTech (AIM) Stock Outpacing Its Medical Peers This Year?

Here is how AIM ImmunoTech Inc. (AIM) and Alzamend Neuro, Inc. (ALZN) have performed compared to their sector so far this year.

Zacks.com featured highlights include The Honest Company, Dutch, AIM ImmunoTech, Masimo and Cognizant Technology Solutions

HNST, BROS, AIM, MASI, and CTSH are spotlighted as top-ranked stocks with rising P/E ratios and strong earnings momentum.

Bet On 5 Top-Ranked Stocks With Rising P/E 

Tap these five stocks with increasing P/E ratios to try out an out-of-the-box approach. These stocks are The Honest Company, Dutch Bros, AIM ImmunoTech, Masimo and Cognizant Technology Solutions.

All You Need to Know About AIM ImmunoTech (AIM) Rating Upgrade to Buy

AIM ImmunoTech (AIM) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

FibroGen (FGEN) Reports Q2 Loss, Lags Revenue Estimates

FibroGen (FGEN) delivered earnings and revenue surprises of -50.22% and -53.52%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

AIM ImmunoTech, Inc. (1100% jump in message volume)AIM ImmunoTech surged in retail discussions after announcing the first new subject was dosed in Phase 2 of its Phase 1b/2 trial for Ampligen and AstraZeneca’s (AZN) Imfinzi in late-stage pancreatic cancer treatment. Several Phase 1 patients who received the highest dose will also be included in Phase 2. The trial, known as DURIPANC, is taking place in the Netherlands and will enroll up to 25 patients in this phase.PepGen, Inc. (700% jump in message volume)PepGen shares and retail chatter <a href="https://stocktwits.com/news-articles/markets/equity/pepgen-stock-heads-for-best-week-since-sept-2022/chdghv2RyH">soared</a> after the company released early clinical data from its FREEDOM-DM1 Phase 1 trial for PGN-EDODM1 in myotonic dystrophy type 1 (DM1), a genetic disorder causing progressive muscle weakness. The company reported dose-dependent splicing correction of 12.3% at 5 mg/kg and 29.1% at 10 mg/kg at 28 days post-dosing.While single-dose studies haven’t shown functional improvements, PepGen sees early signs of benefits with repeat dosing. H.C. Wainwright called the data “very encouraging.”Aeon Biopharma, Inc. (700% jump in message volume)Aeon gained attention after announcing a 1-for-72 reverse stock split to meet NYSE American’s minimum share price requirement. The move took effect on Wednesday, with fractional shares rounded up.Last month, Aeon received a non-compliance notice from NYSE American for failing to meet the $2 million stockholders’ equity requirement. The company reported a $32.1 million stockholders’ deficit as of Sept. 30 and has suffered losses in its last two fiscal years. Aeon has until March 5 to submit a plan to regain compliance.Tiziana Life Sciences Ltd. (600% jump in message volume)Tiziana’s stock buzz jumped after a Nature Neuroscience study showed its nasal anti-CD3 monoclonal antibody significantly reduced neuroinflammation and improved recovery in a preclinical model of traumatic brain injury (TBI). The treatment correlated with less anxiety, reduced cognitive decline, and improved motor skills.Additionally, Tiziana revealed on Tuesday that its nasal anti-CD3 preclinical study is nearing completion and that foralumab could be a novel treatment for long COVID.Moleculin Biotech, Inc.&nbsp;(600% jump in message volume)Moleculin saw heightened retail discussion after announcing a $1.07 per share direct offering of about 3.3 million shares and warrants to an institutional investor, with 6.5 million warrants exercisable at $1.07 per share for five years.The company&nbsp;expected to close the offering on Feb. 26, with Roth Capital Partners as the placement agent. The company said proceeds would be used for working capital and general corporate purposes.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Hand holding test tube over stock data on computer monitor. | Image source: Getty Images

AIM ImmunoTech, PepGen, Aeon, Tiziana, Moleculin: 5 Biotech Stocks That Led Retail Message Growth Last Week

New trial data, a reverse split, and financing moves triggered a spike in retail chatter for these biotech stocks in the week ending Feb. 28, 2025.

This account has been verified as an official AIM representative.

Verified Account

AIM Immunotech

AIM ImmunoTech, Inc. is a immuno-pharma company, which focuses on the research and development of therapeutics to treat multiple types of cancers, various viruses and immune-deficiency disorders. Its products include Alferon N Injection and Ampligen. The Alferon N Injection is a purified, natural source, glycosylated, multispecies alpha interferon product, composed of eight forms of high-purified alpha interferon. The Ampligen is used in the treatment of chronic fatigue syndrome and as a vaccine enhancer for therapeutic and/or preventative development related to influenza and cancer treatments. The company was founded in August 1966 and is headquartered in Ocala, FL.

Current Price	$0.2898
Prev Close	$0.2899
Open	$0.2898
Dividend Yield	0.00%
50-Day Moving Average	$0.6133
Beta	0.52
Avg. Volume	288,458.80
PE Ratio	-0.02

52-Week High	$20.33
52-Week Low	$0.2707
Market Capitalization	$2.36M
EPS (Annual)	-$8.61
Price to Book	-0.09
Revenue Per Employee	$4,631.58

AIM
AIM ImmunoTech

Feed

News

Sentiment

Fundamentals

Info

Latest AIM News

AIMAIM ImmunoTech